Premium
One‐year results of the ICON (ionic versus non‐ionic contrast to obviate worsening nephropathy after angioplasty in chronic renal failure patients) Study
Author(s) -
Giustino Gennaro,
Baber Usman,
Mastoris Ioannis,
Vlachojannis Georgios J.,
Yu Jennifer,
Teirstein Paul S.,
Downey William E.,
Batchelor Wayne B.,
Casterella Peter J.,
Nikolsky Eugenia,
Wong S. Chiu,
Theodoropoulos Kleanthis N.,
Dangas George D.,
Mehran Roxana
Publication year - 2016
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.26106
Subject(s) - iodixanol , medicine , percutaneous coronary intervention , myocardial infarction , cardiology , kidney disease , angioplasty , prospective cohort study , revascularization , contrast induced nephropathy , cardiac catheterization , proteinuria , nephropathy , contrast medium , radiology , kidney , diabetes mellitus , endocrinology
Background Long‐term clinical outcomes after exposure to non‐ionic iso‐osmolar contrast medium (IOCM) or ionic low‐osmolar CM (LOCM) in patients with chronic kidney disease (CKD) undergoing coronary angiography are unclear. Methods The ICON trial was a prospective, double‐blinded, multicentre study that randomly assigned 146 patients with CKD undergoing coronary angiography with or without percutaneous coronary intervention to the non‐ionic IOCM Iodixanol or the ionic LOCM Ioxaglate. We report the 1‐year clinical outcomes. Results After randomization, baseline and procedural characteristics were well‐matched between the two groups. At 1 year, three deaths (4.1%) occurred in the ioxaglate and nine deaths in the iodixanol group (13.6%, P = 0.07). The cardiac death rate at 1 year was 2.7% in the ioxaglate group and 9.1% in the iodixanol group ( P = 0.07). There were no significant differences in the rates of myocardial infarction (1.4% vs. 1.5%; P = 1.00) and repeated revascularization (6.8% vs. 9.1%; P = 0.75). Conclusions The use of ionic LOCM ioxaglate was associated with a numerically lower mortality at 1 year as compared to iodixanol in patients who underwent cardiac catheterization. Future studies evaluating long‐term safety following exposure to different types of CM are warranted. © 2015 Wiley Periodicals, Inc.